In our view, the appointment of Thomas McLain (a recognised leader in diagnostics reimbursement strategy and commercialisation, most recently at Exosome Diagnostics, Inc.) represents a significant step towards achieving national reimbursement of KidneyIntelX™. We continue to expect KidneyIntelX™ to initially follow the CMS (Medicare) ‘crosswalk’ procedure for a test with an existing CPT code (granted by the American Medical Association in July 2019), and believe that national reimbursement could be effective from 1st January 2020, one year ahead of expectations at the time of IPO. Further strengthened by the recent successful £14m (gross) equity capital raise, Renalytix AI remains positioned to generate stellar returns in the kidney disease space, and we reiterate our highly positive stance.
